Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome

Lupus

Volumn 5, Issue 1, 1996, Pages 81-83

  Suarez, I M ^a   Diaz, R A ^a   Aguayo Canela, D ^a   Pujol De La Llave, E ^a  

^a HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

Author keywords

Antiphospholipid syndrome; Chloroquine; Thrombocytopenia

Indexed keywords

ACETYLSALICYLIC ACID; CHLOROQUINE; DANAZOL; PREDNISONE; STEROID;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0030045467     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500116     Document Type: Article

References (18)

1. Lechner K. Lupus anticoagulants and thrombosis. Thromb Haemost 1987; 56: 525-47.
2. Asherson RA, Khamashta MA, Ordi J, et al. The 'primary' antiphosphohpid syndrome: Major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-74.
3. Ordi J, Vilardell M, Oristrell J, et al. Bleeding in patients with lupus anticoagulant. Lancet 1984; 2: 868-9.
4. Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GRV. Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibodies. Br J Haematol 1985; 59: 227-30.
5. Alarcon-Segovia D, Sanchez Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol 1989; 16: 1359-61.
6. Yamazaki M, Asakura H, Matsuda T. Resolution of thrombocytopenia in a patient with lupus anticoagulant who received warfarin therapy. Acta Haematol 1994; 92: 52-3.
7. Shi W, Chang BH, Chesterman CN. β2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants. Blood 1993; 81: 1255-62.
8. Ordi J, Barquinero J. Sindrome antifosfolipido primario. Med Clin (Barc) 1989; 93: 581-7.
9. Sturfelt G, Mousa F, Jonsson H, et al. Recurrent cerebral infraction and the antiphospholipid syndrome: Effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus. Ann Rheume Dis 1990; 49: 939-41.
10. Durand JM, Lefevre P, Kaplanski G, et al. Correction of thrombocytopenia with Dapsone in the primary antiphospholipid syndrome. J Rheumatol 1993; 20: 1777-8.
11. Kavanaug HA. Danazol Therapy in thrombocytopenia associated with the antiphospholipid antibody syndrome. Ann Intern Med 1994; 121: 767-8.
12. Madow BP. Use of anti-malarial drugs as 'desludging' agents in vascular disease processes. JAMA 1960; 172: 1630-3.
13. Carter AE, Eban R, Perret RD. Prevention of postoperative deep venous thrombosis and pulmonary embolism. Br Med J 1971; 1: 312-4.
14. Ernest E, Rose M, Lee R. Modification of trans-operative changes in blood fluidity by hydroxy-chloroquine. A possible explanation for the drug anti-thrombotic effect. Pharmaceutica 1984; 4: 48-52.
15. Hurst NP, French JK, Betts WH, O'Donnell L, Cleland LG. Evidence that antimalarial drugs act as phospholipid analog inhibitors of key pathways of phospholipid metabolism in leucocytes. Br J Rheumatol 1986; 25: 127.
16. Loudon JR. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med 1988; 85: 57-61.
17. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum 1987; 30: 1435-6.
18. Petri M, Hochberg M, Hellman D, et al. Incidence of and predictors of thrombotic events in SLE: Protective role of hidroxychloroquine. Arthritis Rheum 1992; 35: S54.